Fluoresentric Real-Time PCR and Pharmacogenomic Test Development

Fluoresentric (FI) was founded in 2003 by two expert real-time polymerase chain reaction (PCR) assay design and development scientists. FI’s facility is located in Park City, Utah, US. It has a full complement of real-time PCR test development instrumentation for quantification, gene expression, single nucleotide polymorphism (SNP) discovery, and genotyping assays.

FI also has separate suites for assay design, small-to-mid scale manufacturing (including reagent lyophilization), biochemical analysis, and customer instrument development and testing. Each suite is equipped with state-of-the-art laboratory equipment and data analysis technologies.

FI offers a broad range of real-time and conventional PCR nucleic acid testing (NAT) and biochemical analysis and identification services, and expertise in scientific, professional, technical, manufacturing, and quality control. Our services include formulation development, nucleic acid assay design, analytical methods development, validation and reagent stability assessment.

Contract PCR and biochemistry services

FI is your one-stop-provider of all things PCR and biochemistry:

  • Drug effects on gene expression
  • Drug efficacy on biochemical expression
  • NAT design (singleplex, duplex, multiplex and internal positive controls)
  • NAT development (singleplex, duplex, multiplex and internal positive controls)
  • Quality control for NAT reagents (oligonucleotides, buffers and enzymes)
  • NAT validation (specificity, sensitivity, LLOD and LLOQ)
  • NAT reagent stability studies
  • Custom ready-to-use NAT reaction mixes (lyophilized)

Bioanalytical services

Our bioanalytical services include:

  • Analytes: genomic DNA, exogenous DNA, total RNA, mRNA, siRNA, biomolecules, pro-drugs, drugs and metabolites
  • Matrices: any
  • Quantitative real-time PCR, relative gene expression, genotyping services, SNP discovery and target sequence discovery
  • Biochemical expression / content

Custom PCR assay – design, optimization and consumables

FI understands the cost pressures in the pharmaceutical environment. We ensure that we develop products that can be manufactured in a timely and reproducible manner using cost-effective materials. Beginning with a concept, the experts at FI can develop ideas into custom tests and products.

FI provides the following:

  • Consultation to plan how to achieve maximum data recovery per reaction
  • Assay redesign, reoptimization or troubleshooting for existing PCR assays
  • Optimization of NAT assays to your performance criteria
  • High-throughput NAT assay development
  • Quantitative real-time PCR (RT-PCR), and reverse transcription RT-PCR assays
  • Genotyping assays in a variety of probe chemistries
  • Instrumentation usage support
  • Assay reagent development
  • Sample preparation protocol development
  • Custom packaging including lyophilization

In addition, FI offers gene expression with cognate biochemical quantification to confirm bioactivity of pharmaceutical formulations, clinical-sample collection, and preparation solutions.

Pharmacogenomics – drug sensitivity and resistance profiling

FI has developed a patent-pending process for the detection of drug response markers. Examples include:

  • Tuberculosis multiple drug-resistance screening
  • Malaria chloroquine resistance screening
  • MRSA marker screening
  • Human cancer cell resistance to taxanes
  • HIV resistance to nucleoside analogues

PCR sample preparation technologies

Our PCR sample preparation technoloiges include:

  • High-throughput real-time PCR ready sample preparation kits
  • Moderate-throughput real-time PCR ready sample preparation kits
  • Clinical sample nucleic acid extraction kits, suitable for point of care testing
  • Custom sample preparation kit development

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

PROTEO Biotech AG and ARTES Biotechnology GmbH: Strategic Alliance for Marketing of Elafin in Asia, Africa and South America

Kiel - Erkrath, June 19, 2006. PROTEO Biotech AG, a wholly owned subsidiary of PROTEO Inc., USA, has signed a cooperation agreement with ARTES Biotechnology GmbH. The aim of the agreement is the marketing of Elafin, the lead product of PROTEO Biotech AG / PROTEO Inc., in India, Egypt and Argentin

Address
Fluoresentric, Inc.

2700 West Homestead Road

Suite 50

Park City

UT 84098

Other

United States of America

800 808 0490 (Toll free) +1 801 580 0490 +1 435 658 1408 www.fluoresentric.com

Fluoresentric Images

Products and Services

Video

White Papers

Press Release

8 March 2011

Fujifilm Corporation and Merck, known as MSD outside the US and Canada, have announced that they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a leading provider of contract manufacturing and development services for the biopharmaceut

Read more
29 May 2007

ACE Pharmaceuticals today announced that the first patient has entered the Phase III trial also known as the Levamisole trial. This trial was accepted by the EMEA by November 2006. The goal of this trial, which was accepted by the EMEA in November 2006, is to assess the efficacy and sa

Read more
19 June 2006

Kiel - Erkrath, June 19, 2006. PROTEO Biotech AG, a wholly owned subsidiary of PROTEO Inc., USA, has signed a cooperation agreement with ARTES Biotechnology GmbH. The aim of the agreement is the marketing of Elafin, the lead product of PROTEO Biotech AG / PROTEO Inc., in India, Egypt and Argentin

Read more

Regional Offices

Fluoresentric, Inc.

2700 West Homestead Road

Suite 50

Park City

UT 84098

Other

United States of America

800 808 0490 (Toll free) +1 801 580 0490 +1 435 658 1408 www.fluoresentric.com

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.